Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRSPNASDAQ:KRYSNASDAQ:NITENASDAQ:SWTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$43.25+2.7%$36.99$30.04▼$67.88$3.73B1.751.75 million shs2.62 million shsKRYSKrystal Biotech$137.77+1.2%$148.95$122.80▼$219.34$3.96B0.65311,318 shs92,116 shsNITENightstar Therapeutics$29.78+1.4%$25.41$9.59▼$29.55$998.68M2.84185,808 shs126 shsSWTXSpringWorks Therapeutics$46.79+0.1%$43.42$28.21▼$62.00$3.53B0.72.31 million shs2.89 million shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics+0.55%+13.91%+18.16%-0.66%-27.27%KRYSKrystal Biotech-0.63%+8.55%+2.91%-26.40%-17.24%NITENightstar Therapeutics0.00%-1.16%+4.91%+11.87%+15.57%SWTXSpringWorks Therapeutics-0.11%+0.17%+1.06%-8.14%+16.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRSPCRISPR Therapeutics3.1627 of 5 stars4.31.00.00.03.32.50.6KRYSKrystal Biotech4.5648 of 5 stars3.51.00.04.72.53.31.9NITENightstar TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASWTXSpringWorks Therapeutics1.5144 of 5 stars3.12.00.00.02.40.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRSPCRISPR Therapeutics 2.50Moderate Buy$71.7565.92% UpsideKRYSKrystal Biotech 3.00Buy$211.1353.24% UpsideNITENightstar Therapeutics 0.00N/AN/AN/ASWTXSpringWorks Therapeutics 2.13Hold$52.5712.37% UpsideCurrent Analyst Ratings BreakdownLatest NITE, KRYS, SWTX, and CRSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025CRSPCRISPR TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$86.00 ➝ $86.005/20/2025CRSPCRISPR TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$81.00 ➝ $81.005/20/2025CRSPCRISPR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$65.00 ➝ $65.005/16/2025KRYSKrystal BiotechCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$215.00 ➝ $155.005/12/2025SWTXSpringWorks TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$47.00 ➝ $47.005/9/2025CRSPCRISPR TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$56.00 ➝ $42.005/8/2025CRSPCRISPR TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$53.00 ➝ $47.005/7/2025CRSPCRISPR TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$84.00 ➝ $81.005/7/2025CRSPCRISPR TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$84.00 ➝ $82.005/7/2025KRYSKrystal BiotechGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$195.00 ➝ $189.005/7/2025KRYSKrystal BiotechChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$219.00 ➝ $219.00(Data available from 6/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRSPCRISPR Therapeutics$35M106.71N/AN/A$22.52 per share1.92KRYSKrystal Biotech$333.45M11.94$3.50 per share39.38$32.85 per share4.19NITENightstar TherapeuticsN/AN/AN/AN/A$5.89 per shareN/ASWTXSpringWorks Therapeutics$219.67M16.05N/AN/A$10.01 per share4.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRSPCRISPR Therapeutics-$366.25M-$4.52N/AN/AN/A-981.54%-18.46%-15.79%8/4/2025 (Estimated)KRYSKrystal Biotech$10.93M$4.1645.7813.67N/A30.69%11.41%10.40%8/4/2025 (Estimated)NITENightstar Therapeutics-$36.86M-$1.26N/AN/AN/AN/A-30.89%-27.65%N/ASWTXSpringWorks Therapeutics-$325.10M-$3.41N/AN/AN/A-134.73%-46.74%-41.12%8/6/2025 (Estimated)Latest NITE, KRYS, SWTX, and CRSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025SWTXSpringWorks Therapeutics-$0.81-$1.11-$0.30-$1.11$64.19 million$49.09 million5/6/2025Q1 2025CRSPCRISPR Therapeutics-$1.27-$1.58-$0.31-$1.58N/AN/A5/6/2025Q1 2025KRYSKrystal Biotech$1.38$1.20-$0.18$1.20$98.66 million$88.18 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRSPCRISPR TherapeuticsN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/ANITENightstar TherapeuticsN/AN/AN/AN/AN/ASWTXSpringWorks TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRSPCRISPR TherapeuticsN/A22.0722.07KRYSKrystal BiotechN/A7.287.76NITENightstar TherapeuticsN/A8.548.54SWTXSpringWorks TherapeuticsN/A6.166.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRSPCRISPR Therapeutics69.20%KRYSKrystal Biotech86.29%NITENightstar Therapeutics32.83%SWTXSpringWorks TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipCRSPCRISPR Therapeutics4.30%KRYSKrystal Biotech13.70%NITENightstar TherapeuticsN/ASWTXSpringWorks Therapeutics7.83%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRSPCRISPR Therapeutics47386.36 million82.26 millionOptionableKRYSKrystal Biotech21028.90 million24.71 millionOptionableNITENightstar Therapeutics4733.54 millionN/ANot OptionableSWTXSpringWorks Therapeutics23075.35 million68.73 millionOptionableNITE, KRYS, SWTX, and CRSP HeadlinesRecent News About These CompaniesSpringWorks Therapeutics (NASDAQ:SWTX) Sees Large Volume Increase - What's Next?June 9 at 12:46 PM | marketbeat.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Sold by Squarepoint Ops LLCJune 5, 2025 | marketbeat.comRFG Advisory LLC Takes $3.93 Million Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)June 4, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 19,315 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)June 4, 2025 | marketbeat.comSPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTXJune 3, 2025 | businesswire.comNuveen Asset Management LLC Has $6.64 Million Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)May 31, 2025 | marketbeat.comBNP Paribas Financial Markets Makes New $351,000 Investment in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)May 28, 2025 | marketbeat.comSpringWorks Therapeutics (SWTX) Surged on Acquisition NewsMay 27, 2025 | msn.comSpringWorks Therapeutics’ SWOT analysis: biotech stock faces acquisition challengesMay 27, 2025 | investing.comSpringWorks Gets CHMP Nod for Mirdametinib in Rare DiseaseMay 26, 2025 | zacks.comProShare Advisors LLC Has $827,000 Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)May 26, 2025 | marketbeat.comDeutsche Bank AG Increases Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)May 25, 2025 | marketbeat.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Receives Consensus Recommendation of "Hold" from AnalystsMay 25, 2025 | marketbeat.comPalisades Investment Partners LLC Buys 12,154 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)May 24, 2025 | marketbeat.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Sold by Bank of America Corp DEMay 24, 2025 | marketbeat.comSpringWorks gets EU endorsement for genetic disorder treatmentMay 23, 2025 | msn.comSpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PNMay 23, 2025 | globenewswire.comWoodline Partners LP Buys 108,512 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)May 22, 2025 | marketbeat.comZimmer Partners LP Buys New Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)May 22, 2025 | marketbeat.comVelan Capital Investment Management LP Makes New $6.70 Million Investment in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)May 21, 2025 | marketbeat.comRafferty Asset Management LLC Has $4.44 Million Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)May 21, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesUnitedHealth Insiders Double Down: Is UNH Stock a Value Play?By Jeffrey Neal Johnson | May 19, 2025View UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?3 Trades Members of Congress Are Making Right NowBy Chris Markoch | May 23, 2025View 3 Trades Members of Congress Are Making Right NowA Large Oil Supply Draw Could Mean Upside in These 3 Energy NamesBy Gabriel Osorio-Mazilli | June 6, 2025View A Large Oil Supply Draw Could Mean Upside in These 3 Energy NamesPharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t IgnoreBy Sam Quirke | May 14, 2025View Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t IgnoreWill Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off?By Gabriel Osorio-Mazilli | May 22, 2025View Will Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off?NITE, KRYS, SWTX, and CRSP Company DescriptionsCRISPR Therapeutics NASDAQ:CRSP$43.24 +1.16 (+2.74%) As of 02:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Krystal Biotech NASDAQ:KRYS$137.77 +1.69 (+1.24%) As of 02:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Nightstar Therapeutics NASDAQ:NITENightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia. It is also developing NSR-RPGR, a candidate that is in Phase 1/2 clinical trials for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy. In addition, the company is developing NSR-ABCA4, a candidate that is in preclinical development stage for the treatment of Stargardt disease. The company was founded in 2013 and is headquartered in London, the United Kingdom.SpringWorks Therapeutics NASDAQ:SWTX$46.78 +0.04 (+0.07%) As of 02:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Qualcomm: What Monday’s Jump Tells Us About the Stock's Prospects Meta Pulls Ahead of the Mag 7: Analysts Predict a Breakout Year ASML’s AI Edge: How Its EUV Tech Is Creating a New Monopoly Robinhood Drops on S&P Snub—Is a Bigger Pullback Coming? 3 Tightly-Held Growth Stocks Set Up for Short Squeezes Palantir Stock Holds Support, Despite Political Backlash Science Applications International Is a Wicked Hot Buy in June Why Unity Software May Be the AI Breakout No One Saw Coming Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
